-
SCTX share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of SCTX shares has increased $0.30 since the market last closed. This is a 1.66% rise.
-
Last closed at $18.36.
The stock has since risen $0.15 in pre-market trading.
Key terms
About SCTX
Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.
-
Market cap: $297.10M
A market capitalization up to $300 million places SCTX in the micro-capitalization category.
Key terms
Smart score
Latest SCTX news
SCTX Financials
-
SCTX total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
SCTX net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
SCTX earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Key terms
SCTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SCTX Competitors
-
How competitors are chosen
SCTX's competitors are included in the Health Technology sector and Biotechnology group
-
Market cap: $297.10M
A market capitalization up to $300 million places SCTX in the micro-capitalization category.
